A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation

Trial Profile

A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation

Completed
Phase of Trial: Phase III

Latest Information Update: 24 May 2017

At a glance

  • Drugs Glycopyrrolate/indacaterol (Primary) ; Glycopyrrolate; Indacaterol
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Acronyms EXPEDITION; FLIGHT-2
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 24 May 2017 Results of a pooled analysis studies evaluating improvement in SGRQ and TDI total scores in different subgroups of patients from FLIGHT1 and FLIGHT2 studies, presented at the 113th International Conference of the American Thoracic Society.
    • 24 May 2017 Results from analysis of FLIGHT trials (FLIGHT1, FLIGHT2 and FLIGHT3 studies) presented at the 113th International Conference of the American Thoracic Society
    • 24 May 2017 Results of pooled analysis from FLIGHT1 and FLIGHT2 studies evaluating the effect of indacaterol/glycopyrrolate on the night-time total symptom scores presented at the 113th International Conference of the American Thoracic Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top